Core Viewpoint - Sanoma has updated its financial targets, aiming for high single-digit growth in adjusted operating profit from 2026 to 2030, driven by accelerated net sales and earnings growth in its Learning and Media Finland segments [1][2]. Group Financial Targets - The financial targets for Learning include mid single-digit growth in comparable net sales and high single-digit growth in adjusted operating profit [4]. - For Media Finland, the targets are stable comparable net sales and low single-digit growth in adjusted operating profit [4]. Growth Drivers - In Learning, curriculum renewals in key markets like Poland and Spain are expected to enhance organic net sales growth from 2026 to 2030, alongside a shift towards personalized learning and AI integration [2]. - Media Finland is set to benefit from a digital transformation and significant advertising growth, particularly with the anticipated opening of the gambling market in 2027 [3][6]. Financial Metrics - The Group's net debt to adjusted EBITDA target has been revised to below 2.5 from below 3.0 [3][5]. - The updated dividend policy aims for an increasing dividend, representing 40-60% of annual free cash flow [5][9]. Changes in Performance Measures - Sanoma will amend the definition of free cash flow to include lease liabilities, which will better reflect cash available for profit distribution [8][9]. - The payout ratio for dividends is expected to increase, with the 2024 payout ratio projected at 56% under the new definition, compared to 44% previously [9].

Core Insights - The European Commission has approved Dupixent (dupilumab) as the first targeted treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in over a decade, providing a new option for patients aged 12 and older who have not responded adequately to antihistamines [1][4][5] Company Overview - Dupixent is developed jointly by Sanofi and Regeneron, targeting type 2 inflammation by inhibiting interleukin-4 (IL4) and interleukin-13 (IL13) pathways, which are key drivers of CSU [10][12] - The approval is based on the LIBERTY-CUPID phase 3 clinical studies, which demonstrated significant efficacy in reducing itch and hives compared to placebo [2][7][8] Clinical Study Findings - Two phase 3 studies (Study A and Study C) involved 284 patients aged 12 years and older, showing Dupixent significantly reduced urticaria activity and increased the percentage of patients achieving well-controlled disease at 24 weeks [2][7][8] - Study B provided additional safety data for patients who were inadequate responders or intolerant to anti-IgE therapy, confirming Dupixent's efficacy in this subgroup [2][3][7] Market Potential - Approximately 270,000 adults and adolescents in the EU suffer from CSU that remains symptomatic despite standard antihistamine treatment, indicating a significant market opportunity for Dupixent [5][6] - Dupixent is already approved for several chronic inflammatory diseases in over 60 countries, with more than 1.3 million patients treated globally [11][12]

Core Insights - Vivoryon Therapeutics N.V. will report its Q3 2025 financial results and operational progress on December 4, 2025 [1] - The company focuses on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [3] Financial Results Announcement - The financial results for the period ending September 30, 2025, will be published on December 4, 2025 [1] - A conference call and webcast will be held to discuss these results, open to the public [1][2] Conference Call Details - The conference call is scheduled for December 4, 2025, at 3:00 pm CET / 9:00 am EST [2] - Participants can join via phone or webcast, with pre-registration recommended for phone access [2] Company Overview - Vivoryon is a clinical stage biotechnology company focused on innovative small molecule-based medicines for treating inflammatory and fibrotic disorders of the kidney [3] - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]

Core Points - The Global Panda Partners Conference 2025 was held in Chengdu, China, focusing on giant panda conservation and global ecological protection [1][5] - The conference gathered over 600 participants from more than 30 countries to discuss ecological development and cultural exchanges [1][5] Group 1: Giant Panda Conservation - The giant panda's threat level has been downgraded from "Endangered" to "Vulnerable" due to collaborative conservation efforts [2] - The captive giant panda population has reached 808, indicating a sustainable species status [4] Group 2: Ecological Civilization - The conference emphasized the importance of ecological civilization and China's commitment to harmonious development between nature and human activities [3] - The establishment of the Giant Panda National Park and relevant laws has optimized panda habitats significantly [4] Group 3: International Cooperation - The conference served as a platform for international dialogue on ecological protection and cultural exchange [5][6] - Participants engaged in various forums and activities to promote consensus on green development globally [6] Group 4: Venue and Local Significance - Shuangliu District, the conference venue, is recognized for its rapid economic growth and cultural heritage, contributing to its reputation as "China's happiest district" [7]

Group 1 - The annual meeting of shareholders for Central Iron Ore Limited was held on November 25, 2025, where key resolutions were approved [1] - Shareholders elected Richard Homsany, Anthony Howland-Rose, David Deitz, and Paul Richardson as directors [1] - Moore Australia Audit (WA) was appointed as the auditors of the Corporation [2] Group 2 - The continuation of the 10% rolling stock option plan was approved by the shareholders [2]

Promotional Event - ACASPRESSO is offering limited-time Black Friday discounts on its flagship products, the AC21 Semi-Automatic Espresso Machine and the AR-11G Blender, from November 20 to December 1, 2025 [1] - The AC21 Espresso Machine is priced at $359.99, down from the original price of $449.99, while the AR-11G Blender is available for $139.99, reduced from $174.99 [1] AC21 Semi-Automatic Espresso Machine - The AC21 features a smart tamping system that automates grinding, distribution, and tamping, simplifying the espresso-making process [3] - It eliminates the "channeling effect" caused by inconsistent manual pressure, ensuring balanced and richly extracted espresso with a smooth crema [4][5] - The machine includes an OPV intelligent pressure stabilization system and a 15-bar pressure pump, maintaining optimal extraction pressure at 9-bar for a rich espresso [6] - It offers dual-mode brewing: a cold brew mode that takes 2 minutes and 30 seconds and an espresso mode that adheres to professional standards [7] AR-11G Blender - The AR-11G blender utilizes advanced rapid cooling technology, allowing for the creation of smooth frozen beverages without ice, preserving flavor quality [7] - It features six intelligent preset modes for various beverages, including smoothies and iced coffee, and has a 6-hour timer for convenience [8] - The large-capacity design supports up to 68 ounces for cold beverages and 51 ounces for smoothies, suitable for gatherings or personal use [8] - The blender is user-friendly with a refill design, one-touch presets, and a self-serve dispensing handle, making it accessible for beginners [9]

Core Insights - Nokia collaborates with NTT DOCOMO to deploy MantaRay SON in Japan's multi-vendor 5G network, marking a significant advancement in automation and operational efficiency for 5G operations [1][6] - MantaRay SON addresses the complexity of 5G networks by automating routine operations, improving network quality, efficiency, and customer experience while reducing operational costs [2][3] - The integration allows for seamless automation of planning, provisioning, and verification processes, enhancing network performance and enabling closed-loop operations [3][4] Company and Industry Impact - The deployment of MantaRay SON is expected to enhance customer experience and operational efficiency for DOCOMO, aligning with their goal of achieving Level 4 autonomous network operations [4][6] - Nokia's MantaRay SON is a key component of its Service Management and Orchestration framework, leveraging AI to optimize network operations and support DOCOMO's open network initiatives [4][5] - The partnership signifies a shift towards more advanced, AI-driven automation in the telecom industry, with potential implications for cost savings and service quality improvements [4][6]

Core Insights - MoneyHero Limited has announced a strategic partnership with InsureMO to enhance digital insurance offerings in the Philippines through its local brand Moneymax [1][3] - The Philippines has a low insurance penetration rate of approximately 2% of GDP, significantly below the regional average of 4-5%, indicating a substantial market opportunity [2] - The partnership aims to address the underserved motor insurance market, where only about 1 in 3 vehicles has comprehensive coverage [2] Company Overview - MoneyHero Limited operates as a tech- and AI-powered personal finance aggregation platform, providing consumers with tools to compare and choose financial products [6] - The company has a presence in multiple Asian markets, including Singapore, Hong Kong, Taiwan, and the Philippines, with a portfolio of brands including MoneyHero, SingSaver, Money101, Moneymax, and Seedly [6] - As of June 30, 2025, MoneyHero had over 270 commercial partner relationships and approximately 5.3 million monthly unique users [6] Partnership Details - The collaboration with InsureMO will utilize an API-driven platform to streamline the insurance purchasing process for Filipino households, enhancing access and convenience [3][5] - InsureMO's platform supports rapid deployment of new insurance products, allowing insurers to launch offerings via MoneyMax in a matter of weeks [7] - The partnership is expected to improve customer experience by providing real-time quotes and a broader selection of insurance products [7] Market Context - The partnership is positioned to capitalize on the growing demand for digital insurance solutions in the Philippines, where digital distribution can significantly enhance insurance access [5] - MoneyHero aims to replicate successful strategies from other Asian markets to scale its insurance vertical in the Philippines [5] - The initiative is supported by strategic relationships with key insurers in the region, enhancing operational control and customer acquisition capabilities [7]

Core Insights - Junshi Biosciences announced that its JS001sc-002-III-NSCLC study has met its primary endpoints, indicating a successful Phase 3 clinical trial for its subcutaneous formulation of toripalimab in treating recurrent or metastatic non-squamous non-small-cell lung cancer (NSQ-NSCLC) [1][5] - The company plans to submit a new drug application (NDA) to regulatory authorities soon, aiming to enhance treatment accessibility and convenience for patients [1][6] Company Overview - Junshi Biosciences, founded in December 2012, is an innovation-driven biopharmaceutical company focused on discovering, developing, and commercializing novel therapies, with a diverse R&D pipeline of over 50 drug candidates [8][10] - The company has five therapeutic focus areas: cancer, autoimmune, metabolic, neurological, and infectious diseases, and has received approvals for five products in China and international markets [9][8] Clinical Study Details - The JS001sc-002-III-NSCLC study is a multi-center, open-label, randomized Phase 3 clinical trial led by Professor Lin WU from Hunan Cancer Hospital, marking the first Phase 3 study of a domestic anti-PD-1 monoclonal antibody subcutaneous formulation [4][7] - The study results showed that the drug exposure of JS001sc was non-inferior to that of the intravenous formulation, with comparable efficacy and safety profiles [5][6] Market Context - In 2022, China reported 1.06 million new lung cancer cases, with non-small-cell lung cancer (NSCLC) being the predominant subtype, accounting for approximately 85% of cases [2] - Immunotherapy, particularly anti-PD-1 monoclonal antibodies, has become a cornerstone treatment for various cancers, highlighting the urgent need for more convenient administration methods [3][6]

Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the ...